Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.22.00509
Abstract: PURPOSE To present primary and final analyses from the randomized, double-blind, placebo-controlled, phase III iNTEGRATE study, which evaluated the safety and efficacy of ibrutinib with prednisone in previously untreated patients with chronic graft-versus-host disease (cGVHD).… read more here.
Keywords: placebo prednisone; prednisone; ibrutinib prednisone; treatment ... See more keywords